JADE201 builds on clinical proof-of-concept for BAFF-R targeting, adding half-life extension technology to provide extended receptor occupancy with the goal of delivering deeper, more durable B cell depletion with less… Read More
Patients treated with subcutaneous TREMFYA® achieved clinically meaningful results in both clinical remission (36.7%) and endoscopic remission (25.9%) at Week 48 in the Phase 3 ASTRO study Clinical and endoscopic outcomes… Read More
SOUTH SAN FRANCISCO, USA and VANCOUVER, BC – ESSA Pharma Inc is pleased to announce that its Securityholders (as defined below) have approved the acquisition of all of the issued and outstanding common… Read More
Anticipated collaboration with leading academic institutions aims to overcome key barriers in cell and gene therapy by targeting solid tumors, enabling in vivo treatment, and radically reducing manufacturing costs Cytiva… Read More
Canada, TO – Innovative Medicines Canada (IMC) applauds the Government of Ontario for its pioneering announcement of the Funding Accelerated for Specific Treatments (FAST) Program, a new initiative designed to significantly… Read More
